Your browser doesn't support javascript.
loading
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy.
Recondo, Gonzalo; Mahjoubi, Linda; Maillard, Aline; Loriot, Yohann; Bigot, Ludovic; Facchinetti, Francesco; Bahleda, Rastislav; Gazzah, Anas; Hollebecque, Antoine; Mezquita, Laura; Planchard, David; Naltet, Charles; Lavaud, Pernelle; Lacroix, Ludovic; Richon, Catherine; Lovergne, Aurelie Abou; De Baere, Thierry; Tselikas, Lambros; Deas, Olivier; Nicotra, Claudio; Ngo-Camus, Maud; Frias, Rosa L; Solary, Eric; Angevin, Eric; Eggermont, Alexander; Olaussen, Ken A; Vassal, Gilles; Michiels, Stefan; Andre, Fabrice; Scoazec, Jean-Yves; Massard, Christophe; Soria, Jean-Charles; Besse, Benjamin; Friboulet, Luc.
Afiliação
  • Recondo G; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Mahjoubi L; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Maillard A; Department of biostatistics and epidemiology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Loriot Y; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Bigot L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Facchinetti F; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Bahleda R; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Gazzah A; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Hollebecque A; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Mezquita L; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Planchard D; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Naltet C; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Lavaud P; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Lacroix L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Richon C; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Lovergne AA; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • De Baere T; Experimental and Translational Pathology Platform (PETRA), Genomic Platform - Molecular Biopathology unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Tselikas L; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Deas O; Experimental and Translational Pathology Platform (PETRA), Genomic Platform - Molecular Biopathology unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Nicotra C; Department of Clinical Research, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Ngo-Camus M; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Frias RL; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Solary E; XenTech, Evry, France.
  • Angevin E; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Eggermont A; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Olaussen KA; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Vassal G; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Michiels S; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Andre F; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Scoazec JY; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Massard C; Department of Clinical Research, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Soria JC; Department of biostatistics and epidemiology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Besse B; Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800 Villejuif, France.
  • Friboulet L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
NPJ Precis Oncol ; 4: 27, 2020.
Article em En | MEDLINE | ID: mdl-32964129
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Precis Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Precis Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França